Craig Lockhart

Safety and activity of alisertib, an investigational aurora kinase A inhibitor, in patients with breast cancer, small-cell lung cancer, non-small-cell lung cancer, head and neck squamous-cell carcinoma, and gastro-oesophageal adenocarcinoma: a five-arm phase 2 study.

A. DeMichele, B. Melichar, P. Zatloukal, 2015, The Lancet. Oncology.